跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Anti-CD19-CAR
首页
药物
Anti-CD19-CAR
Anti-CD19-CAR
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Anti-CD19 CAR-T cell
申请人: BEIJING MARINO BIOTECHNOLOGY PTY LTD
优先权: 2018
US
Anti-CD19 antibody and CAR-T structure
申请人: TENEOBIO INC
优先权: 2022
CN
ANTI-CD19 ANTIBODIES AND CAR-T STRUCTURES
申请人: TENEOBIO INC
优先权: 2021
EP
US
WO
4 件公开
Monoclonal antibody for detecting anti-CD19 Car expression level and application thereof in activating CD19 CAR-T cells
申请人: SHANGHAI XINGWAN BIOTECHNOLOGY CO LTD
优先权: 2022
CN
NOVEL BISPECIFIC ANTI CD19-CD20 CAR-T CONSTRUCTS AND USES THEREOF
申请人: LAKEFRONT BIOTHERAPEUTICS NV
优先权: 2024
WO
METHODS FOR TREATING LUPUS NEPHRITIS USING ANTI-CD19 CAR-T CELL THERAPIES
申请人: KYVERNA THERAPEUTICS INC
优先权: 2022
CN
EP
US
WO
4 件公开
METHODS FOR TREATING SYSTEMIC SCLEROSIS USING ANTI-CD19 CAR-T CELL THERAPIES
申请人: KYVERNA THERAPEUTICS INC
优先权: 2023
WO
CHIMERIC ANTIGEN RECEPTOR (CAR) COMPRISING AN ANTI-CD19 VHH AS TARGETING DOMAIN
申请人: GENZYME CORP
优先权: 2025
WO
药物
反馈